CancerCAPYBARANCT06544070
Capillary Blood Accuracy
An observational study of Cancer, run by Entia Ltd.
Trial summary
Entia is a health technology company that has developed a blood testing device called Entia Liberty, which analyses blood collected by a finger prick. Entia is sponsoring this research study to compare the results from Entia Liberty finger prick tests to results from the gold-standard laboratory analyser that tests… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Cancer
- What is being tested?
- Entia Liberty System
- Type of treatment
- Medical device
- How many people
- 0 participants
- Where
- No sites listed yet
- Study dates
- 4 Nov 2024to 3 Nov 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adults with a diagnosis of solid tumour cancer who are undergoing systemic anti-cancer therapy (SACT).
Who may be able to join
- Age ≥ 18 years old at the time of study entry
- Patients undergoing systemic anti-cancer therapy (SACT)
- Patients capable of providing written informed consent
- Patients undergoing routine Full Blood Count (FBC) laboratory blood tests as part of the standard of care
- Additional inclusion criteria:
- Phase 1 (Longitudinal, low count data): Neutrophil Count ≤ 1.0 x109/L within 24 hours preceding consenting
- Phase 2 (Low count data): Neutrophil Count ≤ 1.5 x109/L within 24 hours preceding consenting
Who cannot join
- History or current diagnosis of haematological malignancy
- Inadequate use and understanding of the English language, requiring a translator
About this study
Entia is a health technology company that has developed a blood testing device called Entia Liberty, which analyses blood collected by a finger prick. Entia is sponsoring this research study to compare the results from Entia Liberty finger prick tests to results from the gold-standard laboratory analyser that tests blood from the arm, port, or PICC line.
- Conditions
- Cancer
- Being tested
- Entia Liberty System
- Medical subject headings
- Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Entia Liberty SystemDevice
Participants will donate finger-prick blood samples to be tested on the Entia Liberty System. The results will not be used to inform clinical decisions or affect routine clinical care in any way.
| Study group | Role | What they receive |
|---|---|---|
| Phase 1 | Participants who have undergone a laboratory FBC test that has returned a neutrophil count of ≤ 1.0 x109/L who can be consented within 24 hours of the result.
Participants will donate one finger prick sample up to once per day to be tested on the Liberty device. Receives: Device: Entia Liberty System | |
| Phase 2 | Participants who have undergone a laboratory FBC test that has returned a neutrophil count of ≤ 1.5 x109/L who can be consented within 24 hours of the result.
Participants will donate up to 3 finger prick samples to be tested on the Liberty device in a single session. Receives: Device: Entia Liberty System | |
| Phase 3 | Participants who are undergoing a routine venous draw as part of the standard of care as part of SACT toxicity monitoring.
Participants will donate up to 3 finger prick samples to be tested on the Liberty device in a single session. Receives: Device: Entia Liberty System |
What is being measured
The primary outcome is the main question the study is designed to answer.
Validity of of the Liberty System for haematological parameters of interest: Hb, WBC, PLT, ANC
The accuracy of the Liberty System will be measured by comparing the results of finger-prick blood samples that have been analysed using the Liberty System to the results of venous (blood from the arm, port or PICC line) blood samples that have been analysed by a standard laboratory haematology analyser.
Measured: Through study completion, up to 8 days per participant.
Reliability of of the Liberty System for haematological parameters of interest: Hb, WBC, PLT, ANC
To measure the precision of the Liberty System by comparing the results of finger-prick blood samples that have been analysed by the Liberty System to each other, and to venous (blood from the arm, port or PICC line) blood samples that have been analysed by the Liberty System.
Measured: Through study completion, up to 8 days per participant.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Aug 2024
- Study start4 Nov 2024 (estimated)
- Primary completion3 Nov 2025 (estimated)
- Study completion3 Nov 2025 (estimated)
Why it stopped: Change in trial pipeline. Study no longer required.
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Enrolment
- 0 participants (actual)
Sponsor and investigators
- Lead sponsor
- Entia Ltd
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06544070
- Sponsor's protocol ID
- CTM-PRO-00028
- Other IDs
- 347665
- Acronym
- CAPYBARA
- Status last verified
- Sep 2026
- First submitted
- 31 Jul 2024
- Last updated
- 11 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 11 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Capillary Blood Accuracy
- ClinicalTrials.gov ID
- NCT06544070
- Acronym / sponsor ID
- CAPYBARA / CTM-PRO-00028
- Conditions
- Cancer
- Study type
- Observational
- Recruitment status
- WithdrawnReason stopped: Change in trial pipeline. Study no longer required.
- Enrolment
- 0 participants (actual)
- Lead sponsor
- Entia LtdIndustry (pharma, biotech, devices)
- Study start
- 4 Nov 2024 (estimated)
- Primary completion
- 3 Nov 2025 (estimated)
- Study completion
- 3 Nov 2025 (estimated)
- First posted
- 9 Aug 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Entia is a health technology company that has developed a blood testing device called Entia Liberty, which analyses blood collected by a finger prick. Entia is sponsoring this research study to compare the results from Entia Liberty finger prick tests to results from the gold-standard laboratory analyser that tests blood from the arm, port, or PICC line.
Study design
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Phase 1 | – | Device: Entia Liberty SystemParticipants who have undergone a laboratory FBC test that has returned a neutrophil count of ≤ 1.0 x109/L who can be consented within 24 hours of the result. Participants will donate one finger prick sample up to once per day to be tested on the Liberty device. |
| Phase 2 | – | Device: Entia Liberty SystemParticipants who have undergone a laboratory FBC test that has returned a neutrophil count of ≤ 1.5 x109/L who can be consented within 24 hours of the result. Participants will donate up to 3 finger prick samples to be tested on the Liberty device in a single session. |
| Phase 3 | – | Device: Entia Liberty SystemParticipants who are undergoing a routine venous draw as part of the standard of care as part of SACT toxicity monitoring. Participants will donate up to 3 finger prick samples to be tested on the Liberty device in a single session. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Adults with a diagnosis of solid tumour cancer who are undergoing systemic anti-cancer therapy (SACT).
Key inclusion criteria (7 listed)
- Age ≥ 18 years old at the time of study entry
- Patients undergoing systemic anti-cancer therapy (SACT)
- Patients capable of providing written informed consent
- Patients undergoing routine Full Blood Count (FBC) laboratory blood tests as part of the standard of care
- Phase 1 (Longitudinal, low count data): Neutrophil Count ≤ 1.0 x109/L within 24 hours preceding consenting
Key exclusion criteria (2 listed)
- History or current diagnosis of haematological malignancy
- Inadequate use and understanding of the English language, requiring a translator
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Entia Liberty SystemParticipants will donate finger-prick blood samples to be tested on the Entia Liberty System. The results will not be used to inform clinical decisions or affect routine clinical care in any way. | Device | Phase 1, Phase 2, Phase 3 |
Primary outcome
Validity of of the Liberty System for haematological parameters of interest: Hb, WBC, PLT, ANC
Time frame: Through study completion, up to 8 days per participant.
The accuracy of the Liberty System will be measured by comparing the results of finger-prick blood samples that have been analysed using the Liberty System to the results of venous (blood from the arm, port or PICC line) blood samples that have been analysed by a standard laboratory haematology analyser.
Reliability of of the Liberty System for haematological parameters of interest: Hb, WBC, PLT, ANC
Time frame: Through study completion, up to 8 days per participant.
To measure the precision of the Liberty System by comparing the results of finger-prick blood samples that have been analysed by the Liberty System to each other, and to venous (blood from the arm, port or PICC line) blood samples that have been analysed by the Liberty System.
Results and safety
The study was withdrawn before enrolling participants, so there are no results.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Sep 2026.
- Individual participant dataSharing planned: No
Related trials for Cancer
RecruitingPhase 1
A Study to Evaluate the Safety and Antitumor Activity of GS-1206 in Adults With Solid Tumors
Solid Tumor
RecruitingPhase 1
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
Lymphoma, Non-Hodgkin's, Lymphoma, Diffuse Large B-Cell
RecruitingPhase 1/2
Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Enrolling by invitationObservational study
Natural History Study of Early Life Exposures in Agriculture (ELEA)
Prostate Cancer, Leukemia
RecruitingPhase 3
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Breast Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
An observational study of Cancer, run by Entia Ltd.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: withdrawn, as of the sponsor's last update on 11 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was withdrawn before enrolling participants, so there are no results.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Validity of of the Liberty System for haematological parameters of interest: Hb, WBC, PLT, ANC (time frame: Through study completion, up to 8 days per participant.). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Sep 2026.